Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394509 | 0.88 | MAPT (0.56) | L3MBTL1MAPTTDP1SMN1; SMN2CYP2C9 | |
| SCHEMBL2396534 | 0.87 | MAPT (0.55) | L3MBTL1MAPTTDP1SMN1; SMN2CYP2C9 | |
| SCHEMBL4403623 | 0.86 | FOLH1 (0.51) | L3MBTL1MAPTTDP1SMN1; SMN2CYP2C9 | |
| SCHEMBL9540402 | 0.85 | L3MBTL1 (0.67) | L3MBTL1MAPTTDP1SMN1; SMN2CYP2C9 | |
| SCHEMBL1843333 | 0.84 | CLCN2 (0.55) | L3MBTL1MAPTTDP1SMN1; SMN2CYP2C9 | |
| SCHEMBL3245118 | 0.83 | CTSV (0.50) | L3MBTL1MAPTTDP1SMN1; SMN2CYP2C9 | |
| SCHEMBL6286054 | 0.82 | L3MBTL1 (0.81) | L3MBTL1MAPTTDP1SMN1; SMN2CYP2C9 | |
| SCHEMBL27703867 | 0.82 | L3MBTL1 (0.63) | L3MBTL1MAPTTDP1SMN1; SMN2CYP2C9 | |
| SCHEMBL3701442 | 0.82 | PTGER1 (0.60) | L3MBTL1MAPTTDP1PTGER1MAPK1 | |
| SCHEMBL24983833 | 0.79 | PTGER1 (0.60) | L3MBTL1MAPTTDP1SMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349983-B1 | DIFLUORPHENYL DIACYLHYDRAZIDE DERIVATES | MERCK PATENT GMBH (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-8546613-B2 | SGK1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8492440-B2 | Difluorophenyldiacylhydrazide derivatives | MERCK PATENT GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| EP-2242738-B1 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS | MERCK PATENT GMBH (DE) | 2012-03-28 | — | — | EP | disclosed |
| US-20110224302-A1 | DIFLUOROPHENYLDIACYLHYDRAZIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-15 | — | — | US | disclosed |
| EP-2349983-A2 | DIFLUORPHENYL DIACYLHYDRAZIDE DERIVATES | Merck Patent GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20110060050-A1 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS | MERCK PATENT GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| EP-2242738-A1 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS | Merck Patent GmbH (DE) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010060522-A2 | DIFLUORPHENYL DIACYLHYDRAZIDE DERIVATES | MERCK PATENT GMBH (DE) | 2010-06-03 | — | — | WO | disclosed |
| WO-2009103484-A1 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS | MERCK PATENT GMBH (DE) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060050-A1 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS | NCOA1, NR3C2, NCOA2 | L3MBTL1 2152/4885MAPT 2569/4885TDP1 3849/4885 |
| US-20110224302-A1 | DIFLUOROPHENYLDIACYLHYDRAZIDE DERIVATIVES | FGFR1, PKD1, AGTR1 | L3MBTL1 669/4885MAPT 4485/4885TDP1 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.